| Detected | Trial | Change |
|---|---|---|
| 2026-05-30 | NCT06743126 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated… |
Trial sites expanded: 59 -> 66 locations |
| 2026-05-29 | NCT05607095 A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated… |
date change Primary completion pushed: 2026-05-01 -> 2027-05-01 |
| 2026-05-29 | NCT05607095 A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated… |
date change Completion pushed: 2026-05-01 -> 2027-05-01 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06743126 | SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated… | Melanoma, Cutaneous Malignant | Recruiting |
| Phase 2 | |||
| NCT07288203 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | Melanoma (Skin Cancer) | Active, Not Recruiting |
| Phase 1 | |||
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated… | Uveal Melanoma | Recruiting |
| NCT05176470 | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of… | Locally Advanced Melanoma | Active, Not Recruiting |